Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is projected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Viking Therapeutics to announce earnings of ($1.06) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:00 PM ET.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.11. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.58) EPS. On average, analysts expect Viking Therapeutics to post ($4.46) EPS for the current fiscal year and ($4.08) EPS for the next fiscal year.

Viking Therapeutics Price Performance

Shares of VKTX opened at $26.71 on Wednesday. The firm has a market cap of $3.37 billion, a P/E ratio of -5.73 and a beta of 0.66. The stock has a 50 day simple moving average of $31.85 and a two-hundred day simple moving average of $32.96. Viking Therapeutics has a 1 year low of $24.94 and a 1 year high of $43.15.

Insider Buying and Selling

In other Viking Therapeutics news, COO Marianna Mancini sold 18,217 shares of Viking Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $33.47, for a total value of $609,722.99. Following the transaction, the chief operating officer directly owned 422,760 shares of the company’s stock, valued at $14,149,777.20. The trade was a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Greg Zante sold 21,217 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $33.47, for a total value of $710,132.99. Following the completion of the sale, the chief financial officer owned 212,204 shares of the company’s stock, valued at $7,102,467.88. The trade was a 9.09% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 187,951 shares of company stock worth $6,268,442 in the last ninety days. 5.30% of the stock is owned by insiders.

Analysts Set New Price Targets

VKTX has been the topic of several research reports. Wall Street Zen downgraded shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. JPMorgan Chase & Co. cut their price objective on shares of Viking Therapeutics from $75.00 to $65.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. UBS Group assumed coverage on shares of Viking Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $94.00 target price on the stock. Barclays upgraded shares of Viking Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 13th. Finally, Canaccord Genuity Group lowered their price target on shares of Viking Therapeutics from $114.00 to $106.00 and set a “buy” rating for the company in a research note on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Viking Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $98.10.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.